Actively Recruiting
Development of Preclinical Models Derived From Tumors With a Molecular Abnormality of Interest to Test Their Sensitivity to New Anti-tumor Therapies.
Led by Centre Antoine Lacassagne · Updated on 2025-09-29
50
Participants Needed
1
Research Sites
269 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to collect tumor samples from patients carrying a mutation of interest to develop a cell culture technique for "spheroids. The goal is to use these spheroids to model responses to anticancer treatments. Various therapeutic molecules can be tested on these spheroids, enabling the evaluation of the potential of new molecules or the activity of existing ones specifically on the tumor (bearing the mutation of interest) from which the spheroid was developed. Tumor samples will be collected as part of biopsies or surgeries conducted during routine patient care.
CONDITIONS
Official Title
Development of Preclinical Models Derived From Tumors With a Molecular Abnormality of Interest to Test Their Sensitivity to New Anti-tumor Therapies.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older.
- Patient with at least one mutation of interest identified by the investigator.
- Patient with a malignant tumor at a locally advanced or metastatic stage.
- Scheduled tumor tissue sample collection via surgery, radiology, or endoscopy as part of standard care.
- Tumor volume sufficient for analysis and transfer to the research laboratory.
- INR less than 1.5; Platelets greater than 50,000/µL.
- Patient informed about the study and has signed the informed consent form.
- Patient affiliated with social security insurance.
You will not qualify if you...
- Patient with multiple primary malignant tumors.
- Known infection with HIV, Hepatitis B, or Hepatitis C.
- Use of certain blood-thinning medications without possibility of suspension before the procedure (including Clopidogrel, Prasugrel, Ticlopidine, low molecular weight heparin, Fondaparinux, Abciximab, Eptifibatide, Tirofiban, Argatroban, Bivalirudin, Dabigatran etexilate).
- Patient considered vulnerable, including pregnant or breastfeeding women, individuals deprived of liberty, hospitalized without consent, or adults under legal protection unable to consent.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Centre Antoine Lacassagne
Nice, France, 06189
Actively Recruiting
Research Team
S
Study coordinator
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here